Symptomatické neurologické komplikácie sa vyskytujú u 15-30 % pacientov s infekčnou endokarditídou. Zároveň sa u 35-60 % pacientov vyskytujú klinicky nemé mozgové embólie. Staphylococcus aureus je patogén, ktorý najčastejšie spôsobuje postihnutie nervového systému. Uvádzame prípad 67-ročného muža s infekčnou endokarditídou po stomatologickom výkone, ktorý sa prejavil ako spondylodiscitída a mnohopočetná embolizácia do mozgu, vrátane mozgového abscesu, ktorý si vyžiadal neurochirurgickú drenáž. Po 6 týždňoch liečby širokospektrálnymi antibiotikami a komplexnej podpornej terapii sme pacienta prepustili v uspokojivom somatickom a psychickom stave. Pokračuje príprava pacienta na kardiochirurgický výkon.

Symptomatic neurological complications occur in 15-30% of patients with infective endocarditis. At the same time, other clinically silent cerebral embolisms occur in 35-60% of patients. Staphylococcus aureus is the pathogen that causes nervous system involvement most frequently. We report a case of a 67-year-old man with infective endocarditis following a dental procedure that manifested as spondylodiscitis and multiple brain embolization, including a brain abscess that required drainage. After six weeks of treatment with broad-spectrum antibiotics and complex supportive therapy, we discharged the patient in a satisfactory mental and somatic condition. The preparation of the patient for cardiac surgery is ongoing.

• MeSH
• absces mozku diagnostické zobrazování   etiologie   patologie   terapie   MeSH
• discitida diagnostické zobrazování   komplikace   patologie   MeSH
• echokardiografie transezofageální MeSH
• endokarditida * diagnostické zobrazování   farmakoterapie   komplikace   patologie   terapie   MeSH
• extrakce zubů škodlivé účinky   MeSH
• intrakraniální embolie * diagnostické zobrazování   komplikace   patologie   MeSH
• lidé MeSH
• magnetická rezonanční tomografie MeSH
• mitrální insuficience diagnostické zobrazování   etiologie   farmakoterapie   MeSH
• senioři MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• Publikační typ
• kazuistiky MeSH

BACKGROUND: Covert brain infarcts are associated with important neurological morbidity. Their incidence in patients with embolic stroke of undetermined source (ESUS) is unknown. AIMS: To assess the incidence of covert brain infarcts and cerebral microbleeds using MRI in a prospective substudy of the NAVIGATE ESUS randomized trial and to evaluate the effects of antithrombotic therapies. METHODS: At 87 sites in 15 countries, substudy participants were randomly assigned to receive rivaroxaban 15 mg daily or aspirin 100 mg daily and underwent brain MRI near randomization and after study termination. The primary outcome was incident brain infarct (clinical ischemic stroke or covert brain infarct). Brain infarcts and microbleeds were ascertained centrally by readers unaware of treatment. Treatment effects were estimated using logistic regression. RESULTS: Among the 718 substudy participants with interpretable, paired MRIs, the mean age was 67 years and 61% were men with a median of 52 days between the qualifying ischemic stroke and randomization and a median of seven days between randomization and baseline MRI. During the median (IQR) 11 (12) month interval between scans, clinical ischemic strokes occurred in 27 (4%) participants, while 60 (9%) of the remaining participants had an incident covert brain infarct detected by MRI. Assignment to rivaroxaban was not associated with reduction in the incidence of brain infarct (OR 0.77, 95% CI 0.49, 1.2) or of covert brain infarct among those without clinical stroke (OR 0.85, 95% CI 0.50, 1.4). New microbleeds were observed in 7% and did not differ among those assigned rivaroxaban vs. aspirin (HR 0.95, 95% CI 0.52-1.7). CONCLUSIONS: Incident covert brain infarcts occurred in twice as many ESUS patients as a clinical ischemic stroke. Treatment with rivaroxaban compared with aspirin did not significantly reduce the incidence of covert brain infarcts or increase the incidence of microbleeds, but the confidence intervals for treatment effects were wide.Registration: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.

• MeSH
• Aspirin terapeutické užití   MeSH
• cerebrální krvácení farmakoterapie   MeSH
• cévní mozková příhoda * diagnostické zobrazování   farmakoterapie   prevence a kontrola   MeSH
• dvojitá slepá metoda MeSH
• embolická cévní mozková příhoda * MeSH
• inhibitory faktoru Xa terapeutické užití   MeSH
• intrakraniální embolie * diagnostické zobrazování   farmakoterapie   epidemiologie   MeSH
• lidé MeSH
• magnetická rezonanční tomografie MeSH
• mozkový infarkt diagnostické zobrazování   farmakoterapie   etiologie   MeSH
• prospektivní studie MeSH
• rivaroxaban terapeutické užití   MeSH
• senioři MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• randomizované kontrolované studie MeSH

BACKGROUND: The effect of interventions on functional impairment is an important outcome in stroke prevention trials and should be considered as an adjunct to counting discrete events. In the NAVIGATE-ESUS trial, 7213 patients with recent embolic strokes of undetermined source were randomized to rivaroxaban (15 mg once daily) or aspirin (100 mg daily). After 11 months there was no effect on the prevention of recurrent stroke. AIMS: To determine the effect of rivaroxaban compared to aspirin on functional and cognitive outcomes. METHODS: Function and cognition were measured at baseline, 1 year, and study end using the Standard Assessment of Global Everyday Activities (SAGEA), a 15-item scale assessing cognitive, instrumental, and basic activities of daily living as well as mobility, and the Montreal Cognitive Assessment (MoCA). Changes in scores were calculated by subtracting either study end or 1-year scores from baseline, and differences in distributions were compared using the Mann-Whitney U test. SAGEA and MoCA scores were also correlated with recurrent stroke. RESULTS: Follow-up SAGEA scores were available in 6378 (88%) participants. There was no difference in change in function for those allocated to rivaroxaban compared to aspirin (Mann-Whitney U test, p = 0.8), with both distributions having a median (25p,75p) change of 0 (-2,1). Overall, more of those who experienced a recurrent stroke (n=247; mostly minor ischemic), reported functional difficulty at study end versus entry, compared with those who did not (51% versus 30%, chi-square test, p< 0.001), and this was consistent across global regions. There was no difference in the change in cognition by treatment group, nor were recurrent strokes associated with a change in cognition. CONCLUSIONS: Rivaroxaban, compared to aspirin, was not associated with changes in functional or cognitive status in patients with recent ESUS. The SAGEA scale detected changes in functional status associated with recurrent strokes in an international stroke population.

• MeSH
• Aspirin škodlivé účinky   MeSH
• cévní mozková příhoda * diagnóza   farmakoterapie   etiologie   MeSH
• činnosti denního života MeSH
• dvojitá slepá metoda MeSH
• embolická cévní mozková příhoda * MeSH
• inhibitory agregace trombocytů MeSH
• inhibitory faktoru Xa škodlivé účinky   MeSH
• intrakraniální embolie * diagnóza   farmakoterapie   etiologie   MeSH
• kognice MeSH
• lidé MeSH
• rivaroxaban škodlivé účinky   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• randomizované kontrolované studie MeSH

• MeSH
• fatální výsledek MeSH
• fibrilace síní terapie   MeSH
• intrakraniální embolie etiologie   MeSH
• katetrizační ablace škodlivé účinky   MeSH
• lidé středního věku MeSH
• lidé MeSH
• píštěl jícnu etiologie   MeSH
• srdeční síně patologie   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• dopisy MeSH
• kazuistiky MeSH

INTRODUCTION: Elderly cryptogenic ischemic stroke (IS) patients with embolic stroke of undetermined source (ESUS) have a high risk of recurrent IS (RIS) compared to other stroke subtypes. In young ESUS patients, different sources of embolism may be a cause and the risk of RIS remains not enough established. The aim was to assess and compare risk of RIS between ESUS and non ESUS patients <50 years. METHODS: The study set consisted of young acute IS patients <50 years enrolled in the prospective HISTORY (Heart and Ischemic STrOke Relationship studY) study registered on ClinicalTrials.gov (NCT01541163). In all analyzed patients, the brain ischemia was confirmed on CT or MRI. All patients underwent identical diagnostic protocol including TEE and long-term ECG-Holter. Cause of IS was assessed according to the ASCOD classification. RESULTS: Of 320 enrolled patients <50 years, 219 (68.4%) were identified as cryptogenic (119 males, mean age 41.4 ± 7.2 years) and 122 (38.1%) patients fulfilled the ESUS criteria. During the follow-up with a median of 34 months, three (2.5%) ESUS and 5 (5.2%) non-ESUS patients suffered from RIS (p = .471). One-year risk of RIS was 0.008 (95% CI: 0-0.025) for ESUS and 0.036 (95% CI: 0-0.076) for non-ESUS patients (p = .262). CONCLUSION: The risk of RIS was very low in ESUS patients and did not differ from those with non-ESUS. Our finding may indicate that antiplatelet therapy can be effective in the secondary prevention in young ESUS patients if high-risk sources of embolization are excluded extensively.

• MeSH
• cévní mozková příhoda * diagnostické zobrazování   epidemiologie   etiologie   MeSH
• dospělí MeSH
• embolická cévní mozková příhoda * MeSH
• intrakraniální embolie * komplikace   diagnostické zobrazování   epidemiologie   MeSH
• ischemická cévní mozková příhoda * MeSH
• ischemie mozku * komplikace   diagnostické zobrazování   epidemiologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• prospektivní studie MeSH
• rizikové faktory MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND AND PURPOSE: Risks, sites, and predictors of major bleeding during antithrombotic therapies have not been well defined for patients with recent embolic stroke of undetermined source. METHODS: Exploratory analysis of major bleeds defined by International Society of Thrombosis and Hemostasis criteria occurring among 7213 participants in international NAVIGATE (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial) embolic stroke of undetermined source randomized trial comparing rivaroxaban 15 mg daily with aspirin 100 mg daily. RESULTS: During a median follow-up of 11 months, 85 major bleeds occurred. The most frequent site was gastrointestinal (38%), followed by intracranial (29%). Assignment to rivaroxaban (hazard ratio [HR], 2.7 [95% CI, 1.7-4.3]), East Asia region (HR, 2.5 [95% CI, 1.6-3.9]), systolic blood pressure ≥160 mm Hg (HR, 2.2 [95% CI, 1.2-3.8]), and reduced estimated glomerular filtration rate (HR, 1.2 per 10 mL/min per 1.73 m2 decrease, [95% CI, 1.0-1.3]) were independently associated with presence of major bleeds. Five (6%) were fatal. Among 15 patients with intracerebral hemorrhage, 2 (13%) were fatal. There was no evidence of an early high-risk period following initiation of rivaroxaban. The annualized rate of intracerebral hemorrhage was 6-fold higher among East Asian participants (0.67%) versus all other regions (0.11%; HR, 6.3 [95% CI, 2.2-18.0]). Distribution of bleeding sites was similar for rivaroxaban and aspirin. CONCLUSIONS: Among embolic stroke of undetermined source patients participating in an international randomized trial, independent predictors of major bleeding were assignment to rivaroxaban, East Asia region, increased systolic blood pressure, and impaired renal function. East Asia as a region was strongly associated with risk of intracerebral hemorrhage. Estimated glomerular filtration rate should be a consideration for stratifying bleeding risk. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.

• MeSH
• Asijci MeSH
• cerebrální krvácení chemicky indukované   MeSH
• cévní mozková příhoda etiologie   prevence a kontrola   MeSH
• dospělí MeSH
• dvojitá slepá metoda MeSH
• hodnoty glomerulární filtrace MeSH
• inhibitory faktoru Xa škodlivé účinky   MeSH
• intrakraniální embolie komplikace   MeSH
• krvácení chemicky indukované   MeSH
• lidé středního věku MeSH
• lidé MeSH
• rivaroxaban škodlivé účinky   MeSH
• rizikové faktory MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH
• Geografické názvy
• Dálný východ MeSH

BACKGROUND: Non-stenotic intracranial and systemic atherosclerosis are associated with ischemic stroke. We report frequency and response to anticoagulant vs. antiplatelet prophylaxis of patients with embolic stroke of undetermined source (ESUS) who have non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis. METHODS: Exploratory analysis of the international NAVIGATE ESUS randomized trial comparing rivaroxaban 15mg daily with aspirin 100mg daily in 7213 patients with recent ESUS. Among participants with results of intracranial arterial imaging with either computed tomographic angiography (CTA) or magnetic resonance angiography (MRA), the frequency and predictors of non-stenotic intracranial and systemic atherosclerosis and responses to antithrombotic therapy were assessed. RESULTS: Among 4723 participants with available intracranial CTA or MRA results (65% of the trial cohort), the prevalence of intracranial atherosclerosis was 16% (n=739). Patient features independently associated with intracranial atherosclerosis included East Asian region (odds ratio 2.7, 95%CI 2.2,3.3) and cervical carotid plaque (odds ratio 2.3, 95%CI 1.9,2.7), among others. The rate of recurrent ischemic stroke averaged 4.8%/year among those with intracranial atherosclerosis vs. 5.0.%/year for those without (HR 0.95, 95%CI 0.65, 1.4). Among those with intracranial atherosclerosis, the recurrent ischemic stroke rate was higher if assigned to rivaroxaban (5.8%/year) vs. aspirin (3.7%/year), but the difference was not statistically significant (HR 1.6, 95%CI 0.78, 3.3). There was trend for the effect of antithrombotic treatments to be different according to the presence or absence of intracranial atherosclerosis (pinteraction=0.09). Among participants with evidence of systemic atherosclerosis by either history or imaging (n=3820), recurrent ischemic stroke rates were similar among those assigned to rivaroxaban (5.5%/year) vs. aspirin (4.9%/year)(HR 1.1, 95%CI 0.84, 1.5). CONCLUSIONS: East Asia region was the strongest factor associated with intracranial atherosclerosis. There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis.

• MeSH
• Aspirin aplikace a dávkování   škodlivé účinky   MeSH
• časové faktory MeSH
• cévní mozková příhoda diagnostické zobrazování   epidemiologie   prevence a kontrola   MeSH
• dvojitá slepá metoda MeSH
• fibrinolytika aplikace a dávkování   škodlivé účinky   MeSH
• hodnocení rizik MeSH
• inhibitory agregace trombocytů aplikace a dávkování   škodlivé účinky   MeSH
• inhibitory faktoru Xa aplikace a dávkování   škodlivé účinky   MeSH
• intrakraniální arterioskleróza diagnostické zobrazování   farmakoterapie   epidemiologie   MeSH
• intrakraniální embolie diagnostické zobrazování   epidemiologie   prevence a kontrola   MeSH
• lidé středního věku MeSH
• lidé MeSH
• onemocnění periferních arterií diagnostické zobrazování   farmakoterapie   epidemiologie   MeSH
• prevalence MeSH
• recidiva MeSH
• rivaroxaban aplikace a dávkování   škodlivé účinky   MeSH
• rizikové faktory MeSH
• senioři MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH

Background and Purpose- The RE-SPECT ESUS trial (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) tested the hypothesis that dabigatran would be superior to aspirin for the prevention of recurrent stroke in patients with embolic stroke of undetermined source. This exploratory subgroup analysis investigates the impact of age, renal function (both predefined), and dabigatran dose (post hoc) on the rates of recurrent stroke and major bleeding. Methods- RE-SPECT ESUS was a multicenter, randomized, double-blind trial of dabigatran 150 or 110 mg (for patients aged ≥75 years and/or with creatinine clearance 30 to <50 mL/minute) twice daily compared with aspirin 100 mg once daily. The primary outcome was recurrent stroke. Results- The trial, which enrolled 5390 patients from December 2014 to January 2018, did not demonstrate superiority of dabigatran versus aspirin for prevention of recurrent stroke in patients with embolic stroke of undetermined source. However, among the population qualifying for the lower dabigatran dose, the rate of recurrent stroke was reduced with dabigatran versus aspirin (7.4% versus 13.0%; hazard ratio, 0.57 [95% CI, 0.39-0.82]; interaction P=0.01). This was driven mainly by the subgroup aged ≥75 years (7.8% versus 12.4%; hazard ratio, 0.63 [95% CI, 0.43-0.94]; interaction P=0.10). Stroke rates tended to be lower with dabigatran versus aspirin with declining renal function. Risks for major bleeding were similar between treatments, irrespective of renal function, but with a trend for lower bleeding rates with dabigatran versus aspirin in older patients. Conclusions- In subgroup analyses of RE-SPECT ESUS, dabigatran reduced the rate of recurrent stroke compared with aspirin in patients qualifying for the lower dose of dabigatran. These results are hypothesis-generating. Aspirin remains the standard antithrombotic treatment for patients with embolic stroke of undetermined source. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT02239120.

• MeSH
• Aspirin * aplikace a dávkování   farmakokinetika   MeSH
• cévní mozková příhoda * krev   farmakoterapie   MeSH
• dabigatran * aplikace a dávkování   farmakokinetika   MeSH
• dvojitá slepá metoda MeSH
• fibrinolytika * aplikace a dávkování   farmakokinetika   MeSH
• intrakraniální embolie * krev   farmakoterapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nemoci ledvin * krev   farmakoterapie   MeSH
• recidiva MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH

Devětatřicetiletý muž s anamnézou plastiky bikuspidální aortální chlopně byl přijat po autonehodě do Fakultní nemocnice Ostrava pro pravostrannou hemiparézu, zpomalené psychomotorické tempo a dezorientaci. Vstupní výpočetní tomografie (CT) prokázala subarachnoidální krvácení temporo-parietálně. Magnetická rezonance (MR) mozku odhalila difuzně lokalizovaná prokrvácená ischemická ložiska. Z ostatních vážných poranění měl nemocný rupturu sleziny s následným hemoperitoneem, která si vynutila urgentní splenektomii. V klinickém obraze nemocného dominovala neurologická symptomatologie, doplněná o petechie na končetinách a průkaz Staphylococcus aureus v likvoru i v hemokulturách. Z tohoto důvodu byla stanovena pracovní diagnóza meningoencefalitidy a nemocný byl léčen kombinací antibiotik. Vstupní transtorakální i transezofageální echokardiografické vyšetření bylo negativní. Teprve kontrolní jícnová echokardiografie, provedená s odstupem dvou týdnů od první pro recidivu febrilií, detekovala vegetace na aortální, mitrální chlopni a absces prominující na síňovou stranu předního mitrálního cípu. Vzhledem k nálezu vegetací byla přehodnocena diagnóza na infekční endokarditidu se septickými embolizacemi do mozku. Pro selhání konzervativní terapie infekční endokarditidy byla provedena náhrada aortální a mitrální chlopně, následovaná protrahovanou antibiotickou léčbou dle citlivosti. Dodatečným anamnestickým šetřením bylo zjištěno, že měsíc před manifestací onemocnění pacient utrpěl řezné poranění bérce, což mohla být vstupní brána infekce. Kazuistika prezentuje případ nemocného s obtížně a opožděně diagnostikovanou infekční endokarditidou, kde razantní antibiotická i chirurgická léčba vedla k plnému vyléčení nemocného.

A 39-year-old male with a history of bicuspid aortic valvuloplasty was admitted after a car accident for right-sided hemiparesis, cognitive slowing, and disorientation to the Teaching Hospital in Ostrava. Computed tomography (CT) at admission detected subarachnoidal bleeding in the temporoparietal region. Moreover, magnetic resonance imaging (MRI) detected small diffuse ischaemic lesions surrounded by microbleeds. Amongst other major injury, the patient suffered from splenic rupture, which led to urgent splenectomy. Major symptoms were of neurological origin, accompanied by forearm petechia and confirmed presence of Staphylococcus aureus in both blood samples and cerebrospinal fluid. Therefore preliminary diagnosis of meningoencephalitis was established and the patient was treated with combination of antibiotics. Transthoracic and transesophageal echocardiography at admission was negative. Not until the second echocardiography, performed two weeks after the first one, due to elevated body temperature, vegetations on both aortic and mitral valve and the abscess on atrial side of anterior mitral valve leaflet were observed. Therefore the meaning of petechia was rethought, and a new diagnosis of infective endocarditis (IE) with septic brain emboli was established. Due to the apparent failure of conservative treatment, the patient underwent aortic and mitral valve replacement, followed by prolonged cultivation-based antibiotic therapy. In addition, one month before the presentation patient suffered from cut injury of his shank, which may have been the entrance point of infection. This case report presents an elaborate and delayed IE diagnosis where both vigorous antibiotic and surgical treatment led to full recovery of the patient.

• Klíčová slova
• abdominalgie,
• MeSH
• antibakteriální látky terapeutické užití   MeSH
• bolest etiologie   MeSH
• chirurgická náhrada chlopně MeSH
• dopravní nehody MeSH
• dospělí MeSH
• echokardiografie transezofageální MeSH
• endokarditida * chirurgie   diagnóza   etiologie   patologie   MeSH
• hemoperitoneum diagnostické zobrazování   MeSH
• horečka etiologie   MeSH
• intrakraniální embolie MeSH
• ischemie mozku diagnostické zobrazování   patologie   MeSH
• lidé MeSH
• magnetická rezonanční tomografie MeSH
• meningoencefalitida diagnóza   MeSH
• mozek diagnostické zobrazování   patologie   MeSH
• neurologické manifestace * MeSH
• paréza etiologie   MeSH
• plíce diagnostické zobrazování   patologie   MeSH
• počítačová rentgenová tomografie MeSH
• poranění dolní končetiny komplikace   MeSH
• purpura etiologie   MeSH
• ruptura sleziny chirurgie   diagnostické zobrazování   MeSH
• splenektomie MeSH
• srdeční chlopně chirurgie   patologie   MeSH
• stafylokokové infekce etiologie   krev   mozkomíšní mok   MeSH
• Staphylococcus aureus patogenita   MeSH
• subarachnoidální krvácení diagnostické zobrazování   patologie   MeSH
• terapie neúspěšná MeSH
• výsledek terapie MeSH
• zmatenost etiologie   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• kazuistiky MeSH

Importance: The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF). Objective: To analyze whether rivaroxaban is associated with a reduction of recurrent stroke among patients with ESUS who have an increased risk of AF. Design, Setting, and Participants: Participants were stratified by predictors of AF, including left atrial diameter, frequency of premature atrial contractions, and HAVOC score, a validated scheme using clinical features. Treatment interactions with these predictors were assessed. Participants were enrolled between December 2014 and September 2017, and analysis began March 2018. Intervention: Rivaroxaban treatment vs aspirin. Main Outcomes and Measures: Risk of ischemic stroke. Results: Among 7112 patients with a mean (SD) age of 67 (9.8) years, the mean (SD) HAVOC score was 2.6 (1.8), the mean (SD) left atrial diameter was 3.8 (1.4) cm (n = 4022), and the median (interquartile range) daily frequency of premature atrial contractions was 48 (13-222). Detection of AF during follow-up increased for each tertile of HAVOC score: 2.3% (score, 0-2), 3.0% (score, 3), and 5.8% (score, >3); however, neither tertiles of the HAVOC score nor premature atrial contractions frequency impacted the association of rivaroxaban with recurrent ischemic stroke (P for interaction = .67 and .96, respectively). Atrial fibrillation annual incidence increased for each tertile of left atrial diameter (2.0%, 3.6%, and 5.2%) and for each tertile of premature atrial contractions frequency (1.3%, 2.9%, and 7.0%). Among the predefined subgroup of patients with a left atrial diameter of more than 4.6 cm (9% of overall population), the risk of ischemic stroke was lower among the rivaroxaban group (1.7% per year) compared with the aspirin group (6.5% per year) (hazard ratio, 0.26; 95% CI, 0.07-0.94; P for interaction = .02). Conclusions and Relevance: The HAVOC score, left atrial diameter, and premature atrial contraction frequency predicted subsequent clinical AF. Rivaroxaban was associated with a reduced risk of recurrent stroke among patients with ESUS and moderate or severe left atrial enlargement; however, this needs to be independently confirmed before influencing clinical practice.

• MeSH
• Aspirin terapeutické užití   MeSH
• cévní mozková příhoda farmakoterapie   MeSH
• fibrilace síní MeSH
• inhibitory agregace trombocytů terapeutické užití   MeSH
• inhibitory faktoru Xa terapeutické užití   MeSH
• intrakraniální embolie farmakoterapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• recidiva MeSH
• rivaroxaban terapeutické užití   MeSH
• rizikové faktory MeSH
• sekundární prevence MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH